{
    "nctId": "NCT02525211",
    "briefTitle": "Continues Cicatricial Perfusion of Ropivacaine Versus Placebo After Mastectomy : Rehabilitation After Treatment",
    "officialTitle": "Double-blind Randomized Prospective Phase III Study of a Continues Cicatricial Perfusion of Ropivacaine Versus Placebo After Mastectomy : Rehabilitation After Treatment of the Postoperative Pain From Hospital to Home",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 59,
    "primaryOutcomeMeasure": "Delay to obtain the three criteria of premature recovery after mastectomy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Women \\> 18 years,\n* Operated for a breast cancer by mastectomy with or without lymph node dissection, without immediate reconstruction,\n* Capable of understanding the antalgic protocol,\n* No contraindication to the local anesthesics,\n* Social security affiliation,\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Preoperative radiotherapy,\n* Local infection,\n* Contra-indication to the local anesthetic or to CCP,\n* Contra-indication for the use of morphine,\n* Contra-indication for the use of remifentanil,\n* Addiction to opioid analgesics know or not,\n* Allergy to local anesthetics,\n* Hepatic or renal impairment grim known,\n* Previous surgery on the operated breast,\n* Pregnant women, or child-bearing potential, or lactating women,\n* Patient deprived of liberty or under supervision of a guardian.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}